All Clinical Trials in Canada

A listing of 3905 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

tDCS Plus Varenicline for Smoking Cessation

NCT06798324

Recruiting

The goal of this clinical trial is to determine if active transcranial direct current stimulation (tDCS) plus varenicline is an effective, safe and accessible treatment option for smoking cessation. The main questions this trial aims to answer are: 1. Does active tDCS plus varenicline improve short-term and long-term smoking abstinence rates compared to sham tDCS plus varenicline? 2. Are the safety profiles between active tDCS plus varenicline and sham tDCS plus varenicline different? The tDCS... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

08/07/2025

Locations: Centre for Addiction and Mental Health, Toronto, Ontario

Conditions: Nicotine Dependence, Tobacco Smoking, Smoking Cessation, Nicotine Use Disorder, Tobacco Use Disorder, Substance Use Disorders

Learn More ›

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06052306

Recruiting

Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new treatment options for participant(s) with prostate cancer in recent years, the cancer often returns and worsens. The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for participants with mCRPC who have already received available treatments or have few treatment options available. It works by binding to a protein on the surface of the cancer cells called prostate specific membrane antigen (PSMA). As it gives off a type of radioactivity that travels a very short distance, it kills the nearby (cancer) cells that express PSMA. The main purpose of this first-in-human study in participants with mCRPC is to learn: * How safe different doses of 225Ac-pelgi are. * To what degree medical problems caused by 225Ac-pelgi can be tolerated by the participants? * Which dose of 225Ac-pelgi is optimal for treatment (safe and working well)? * How good is 225Ac-pelgi's anticancer activity? To answer this, the researchers will look at: * The number and severity of medical problems that the participants have after treatment with 225Ac-pelgi (per dose level). * The ratio of medical problems and anticancer activity per dose. * Anticancer activity of the optimal 225Ac-pelgi dose as proportion of participants who have at least halved prostate-specific antigen (PSA) levels after 12 weeks of treatment or later and/or shrunken or no longer detectable tumors. * The lowest PSA level reached after treatment start. Doctors keep track of all medical problems (also called adverse events) that participants have during the study, even if they do not think that they might be related to the study treatment. Anticancer activity is measured using cancer imaging techniques and change in blood level of a protein called PSA. PSA is made by normal and by cancerous cells in the body. The PSA level is taken as a marker for prostate cancer development and is usually elevated in participants with mCRPC. In addition, researchers want to find out how 225Ac-pelgi moves into, through and out of the body. The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose and schedule that can be given in the second part of the study. For this, each participant will receive one of the predefined increasing doses of 225Ac-pelgi as an infusion into the vein. All participants in part 2, called dose expansion, will receive the most appropriate dose and schedule identified from the first part of the study. More than one dose level or schedule from part 1 may be tested. Both the participants and the study team know what treatment the participants will take. Participants in this study will take the study treatment 225Ac-pelgi once in a period of 6 weeks called a cycle. Each participant will have 4 of these treatment cycles, if the participant benefits from the treatment. Each participant will be in the study for up to nearly six years, including a first test (screening) phase of a maximum of 30 days, up to 12 months of treatment depending on the participant's benefit, and a follow-up phase of 60 months after the end of treatment. The following visits to the study site are planned: 2 during the screening phase, 8 in the first treatment cycle, 7 in subsequent cycles, and a visit 6 to 12 weeks after the last dose. In the following 12 months, visits are planned every 6 weeks and during the next 48 months phone calls or clinic visits are planned approximately every 12 weeks. In addition, a sub study during the dose escalation part will gather information on the distribution of the study treatment in the body, the proportion that binds to the cancer cells, and the resulting radiation at the tumor site. During the study, the study team will: * Do physical examinations * Check vital signs such as blood pressure, heart rate, and body temperature * Take blood, and urine samples * Examine heart health using echocardiogram and electrocardiogram (ECG) * Take tumor samples * Track 225Ac-pelgi in the body using gamma imaging (generally available at all study sites) * Check the tumor status using PET (positron emission tomography), CT (computed tomography) or MRI (magnetic resonance imaging) and bone scan * Ask questions about the impact of the disease on the participants' wellbeing and activities of daily life (Eastern Cooperative Oncology Group Performance status (ECOG PS)). Read Less

Gender:

MALE

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: City of Hope - Duarte Cancer Center, Duarte, California +29 locations

City of Hope - Duarte Cancer Center, Duarte, California

University of Minnesota Medical Center, Minneapolis, Minnesota

XCancer Omaha, Omaha, Nebraska

University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas

Utah Cancer Specialists (UCS) (Intermountain Hematology - Oncology Associates) - UCS Cancer Center, Salt Lake City, Utah

Cross Cancer Institute, Clinical Trials Unit, Edmonton, Alberta

BC Cancer - Vancouver Site, Vancouver, British Columbia

Juravinski Cancer Centre - Clinical Trials Department, Hamilton, Ontario

Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal, Quebec

McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM), Montreal, Quebec

Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont, Sherbrooke, Not set

Kuopio University Hospital, Kuopio, Pohjois-Savo

HUS, Meilahden sairaala, Helsinki, Uusimaa

Docrates Mehiläinen Syöpäsairaala, Helsinki, Uusimaa

Tampere University Hospital, Tampere, Not set

CRST Clinical Research Services Turku, Turku, Not set

Istituto Europeo di Oncologia s.r.l - Medicina Nucleare, Milano, Not set

IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica, Napoli, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Erasmus Medisch Centrum, Rotterdam, Not set

Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH, Göteborg, Not set

Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet, Lund, Not set

Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC, Stockholm, Not set

Akademiska Sjukhuset - Fas-I-enheten, Uppsala, Not set

Kantonsspital Baden, Baden, Aargau

Cambridge University Hospitals NHS Foundation Trust | Addenbrookes Hospital - Clinical Research Centre, Cambridge, Cambridgeshire

Royal Marsden NHS Trust (Surrey), Sutton, Surrey

University College London Hospitals NHS Foundation Trust, London, Not set

The Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Cancer Trials Research Centre, Newcastle upon Tyne, Not set

Conditions: Metastatic Castration-resistant Prostate Cancer

Learn More ›

Saddle Block With IT Morphine for Penile Inversion Vaginoplasty

NCT06556121

Recruiting

Penile Inversion Vaginoplasty (PIV) is a transition-related surgery (TRS) that is associated with severe postoperative pain. The optimal pain management strategies for this surgery remain unknown. We hypothesized that the addition of a saddle block with intrathecal morphine would yield clinically important analgesic benefits.

Gender:

MALE

Ages:

Between 18 years and 70 years

Trial Updated:

08/07/2025

Locations: Women's College Hospital, Toronto, Ontario

Conditions: Pain, Postoperative

Learn More ›

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200

Recruiting

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: GSK Investigational Site, Tucson, Arizona +252 locations

GSK Investigational Site, Tucson, Arizona

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, New Haven, Connecticut

GSK Investigational Site, Washington, District of Columbia

GSK Investigational Site, Deerfield Beach, Florida

GSK Investigational Site, Fort Lauderdale, Florida

GSK Investigational Site, Marietta, Georgia

GSK Investigational Site, Chicago, Illinois

GSK Investigational Site, Naperville, Illinois

GSK Investigational Site, Westwood, Kansas

GSK Investigational Site, Lexington, Kentucky

GSK Investigational Site, Louisville, Kentucky

GSK Investigational Site, Baton Rouge, Louisiana

GSK Investigational Site, Bethesda, Maryland

GSK Investigational Site, Ann Arbor, Michigan

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Minneapolis, Minnesota

GSK Investigational Site, Joplin, Missouri

GSK Investigational Site, Saint Louis, Missouri

GSK Investigational Site, Grand Island, Nebraska

GSK Investigational Site, Omaha, Nebraska

GSK Investigational Site, Lebanon, New Hampshire

GSK Investigational Site, Bronx, New York

GSK Investigational Site, New York, New York

GSK Investigational Site, Durham, North Carolina

GSK Investigational Site, Akron, Ohio

GSK Investigational Site, Cincinnati, Ohio

GSK Investigational Site, Cleveland, Ohio

GSK Investigational Site, Oklahoma City, Oklahoma

GSK Investigational Site, Pittsburgh, Pennsylvania

GSK Investigational Site, Sioux Falls, South Dakota

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, Richmond, Virginia

GSK Investigational Site, Appleton, Wisconsin

GSK Investigational Site, Buenos Aires, Not set

GSK Investigational Site, Capital Federal, Not set

GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Not set

GSK Investigational Site, Cordoba, Not set

GSK Investigational Site, Mar del Plata, Not set

GSK Investigational Site, Rosario, Not set

GSK Investigational Site, San Miguel de TucumAn, Not set

GSK Investigational Site, Santa Fe, Not set

GSK Investigational Site, Newcastle, New South Wales

GSK Investigational Site, St Leonards, New South Wales

GSK Investigational Site, Woolangabba, Queensland

GSK Investigational Site, Heidelberg, Victoria

GSK Investigational Site, Melbourne, Victoria

GSK Investigational Site, Aalst, Not set

GSK Investigational Site, Bruxelles, Not set

GSK Investigational Site, Edegem, Not set

GSK Investigational Site, Gent, Not set

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, LiEge, Not set

GSK Investigational Site, Roeselare, Not set

GSK Investigational Site, Barretos, Not set

GSK Investigational Site, Lages, Not set

GSK Investigational Site, Natal, Not set

GSK Investigational Site, Porto Alegre, Not set

GSK Investigational Site, Salvador, Not set

GSK Investigational Site, Sao Jose Do Rio Preto, Not set

GSK Investigational Site, Sao Paulo, Not set

GSK Investigational Site, Teresina, Not set

GSK Investigational Site, VitOria, Not set

GSK Investigational Site, Edmonton, Alberta

GSK Investigational Site, Halifax, Nova Scotia

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Beijing, Not set

GSK Investigational Site, Changchun, Not set

GSK Investigational Site, Chengdu, Not set

GSK Investigational Site, Chongqing, Not set

GSK Investigational Site, Guangzhou, Not set

GSK Investigational Site, Hangzhou, Not set

GSK Investigational Site, Harbin, Not set

GSK Investigational Site, Jinan, Not set

GSK Investigational Site, Kunming, Not set

GSK Investigational Site, Meizhou, Not set

GSK Investigational Site, Nanchang, Not set

GSK Investigational Site, Shanghai, Not set

GSK Investigational Site, Shenzhen, Not set

GSK Investigational Site, Taiyuan, Not set

GSK Investigational Site, Tianjin, Not set

GSK Investigational Site, Wuhan, Not set

GSK Investigational Site, Xiamen, Not set

GSK Investigational Site, Yangzhou, Not set

GSK Investigational Site, Zhengzhou, Not set

GSK Investigational Site, Tallinn, Not set

GSK Investigational Site, Tartu, Not set

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Turku, Not set

GSK Investigational Site, Lyon, Not set

GSK Investigational Site, Marseille Cedex 5, Not set

GSK Investigational Site, Nantes cedex 1, Not set

GSK Investigational Site, Paris, Not set

GSK Investigational Site, Pessac cedex, Not set

GSK Investigational Site, Rennes Cedex, Not set

GSK Investigational Site, Rouen Cedex, Not set

GSK Investigational Site, Saint-Priest en Jarez, Not set

GSK Investigational Site, Suresnes, Not set

GSK Investigational Site, Toulouse Cedex 9, Not set

GSK Investigational Site, Villejuif Cedex, Not set

GSK Investigational Site, Berlin, Not set

GSK Investigational Site, Duesseldorf, Not set

GSK Investigational Site, Frankfurt, Not set

GSK Investigational Site, Halle, Not set

GSK Investigational Site, Luebeck, Not set

GSK Investigational Site, Mannheim, Not set

GSK Investigational Site, MUnchen, Not set

GSK Investigational Site, Munchen, Not set

GSK Investigational Site, Athens, Not set

GSK Investigational Site, Thessaloniki, Not set

GSK Investigational Site, Cagliari, Not set

GSK Investigational Site, Genova, Not set

GSK Investigational Site, Milano, Not set

GSK Investigational Site, Napoli, Not set

GSK Investigational Site, Padova, Not set

GSK Investigational Site, Pisa, Not set

GSK Investigational Site, Reggio Emilia, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Rozzano MI, Not set

GSK Investigational Site, Aichi, Not set

GSK Investigational Site, Chiba, Not set

GSK Investigational Site, Fukuoka, Not set

GSK Investigational Site, Hokkaido, Not set

GSK Investigational Site, Hyogo, Not set

GSK Investigational Site, Ibaraki, Not set

GSK Investigational Site, Kanagawa, Not set

GSK Investigational Site, Kyoto, Not set

GSK Investigational Site, Okayama, Not set

GSK Investigational Site, Osaka, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Daegu, Not set

GSK Investigational Site, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, DF, Not set

GSK Investigational Site, Guadalajara, Not set

GSK Investigational Site, Mexico City, Not set

GSK Investigational Site, Oaxaca, Not set

GSK Investigational Site, San Pedro Garza Garcia, Not set

GSK Investigational Site, Tijuana, Not set

GSK Investigational Site, Breda, Not set

GSK Investigational Site, Maastricht, Not set

GSK Investigational Site, Nijmegen, Not set

GSK Investigational Site, Utrecht, Not set

GSK Investigational Site, Bergen, Not set

GSK Investigational Site, Kristiansand, Not set

GSK Investigational Site, Lrenskog, Not set

GSK Investigational Site, Oslo, Not set

GSK Investigational Site, Stavanger, Not set

GSK Investigational Site, Tromsoe, Not set

GSK Investigational Site, Punta Pacifica Panama City Panama, Not set

GSK Investigational Site, Almada, Not set

GSK Investigational Site, Coimbra, Not set

GSK Investigational Site, Lisboa, Not set

GSK Investigational Site, Badajoz, Not set

GSK Investigational Site, BaracaldoVizcaya, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, COrdoba, Not set

GSK Investigational Site, Elche Alicante, Not set

GSK Investigational Site, Granada, Not set

GSK Investigational Site, JaEn, Not set

GSK Investigational Site, L'Hospitalet De Llobrega, Not set

GSK Investigational Site, Las Palmas De Gran Canar, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, MAlaga, Not set

GSK Investigational Site, Oviedo, Not set

GSK Investigational Site, Pamplona, Not set

GSK Investigational Site, San Sebastian, Not set

GSK Investigational Site, Santander, Not set

GSK Investigational Site, Sevilla, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Zaragoza, Not set

GSK Investigational Site, Eskilstuna, Not set

GSK Investigational Site, Goteborg, Not set

GSK Investigational Site, Linkoping, Not set

GSK Investigational Site, Malmo, Not set

GSK Investigational Site, Stockholm, Not set

GSK Investigational Site, Uppsala, Not set

GSK Investigational Site, Kaohsiung, Not set

GSK Investigational Site, Tainan, Not set

GSK Investigational Site, Taipei, Not set

GSK Investigational Site, Taoyuan, Not set

GSK Investigational Site, Ankara, Not set

GSK Investigational Site, Istanbul, Not set

GSK Investigational Site, Birmingham, Not set

GSK Investigational Site, Chelmsford, Not set

GSK Investigational Site, Cheltenham, Not set

GSK Investigational Site, Edinburgh, Not set

GSK Investigational Site, Hull, Not set

GSK Investigational Site, Leeds West Yorkshire, Not set

GSK Investigational Site, London, Not set

GSK Investigational Site, Manchester, Not set

GSK Investigational Site, Sutton, Not set

Conditions: Colonic Neoplasms, Neoplasms, Colon

Learn More ›

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437

Recruiting

The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).

Gender:

ALL

Ages:

1 year and above

Trial Updated:

08/07/2025

Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +11 locations

Conditions: Propionic Acidemia

Learn More ›

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315

Recruiting

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A,... Read More

Gender:

ALL

Ages:

Between 2 years and 5 years

Trial Updated:

08/06/2025

Locations: Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona +73 locations

Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona

Allervie Clinical Research - Destin- Site Number : 8400016, Destin, Florida

EMDA Clinical Research- Site Number : 8400026, Miami, Florida

Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400011, Chicago, Illinois

Allergy and Asthma Specialist- Site Number : 8400002, Owensboro, Kentucky

Mayo Clinic Hospital Rochester- Site Number : 8400008, Rochester, Minnesota

UBMD Pediatrics- Site Number : 8400013, Buffalo, New York

Boston Children's Health Physicians - Hawthorne- Site Number : 8400010, Hawthorne, New York

UNC Children's Hospital- Site Number : 8400005, Chapel Hill, North Carolina

Cincinnati Children's Hospital Medical Center- Site Number : 8400004, Cincinnati, Ohio

University Hospitals Cleveland Medical Center- Site Number : 8400015, Cleveland, Ohio

Vanderbilt University Medical Center- Site Number : 8400024, Nashville, Tennessee

South Texas Medical Research Institute - TTS Research- Site Number : 8400022, Boerne, Texas

Investigational Site Number : 0320008, Buenos Aires, Ciudad De Buenos Aires

Investigational Site Number : 0320005, Rosario, Santa Fe

Investigational Site Number : 0320002, Buenos Aires, Not set

Investigational Site Number : 0320003, Buenos Aires, Not set

Investigational Site Number : 0320001, Buenos Aires, Not set

Investigational Site Number : 0320009, Corrientes, Not set

Investigational Site Number : 0320006, Córdoba, Not set

Investigational Site Number : 0320004, Mendoza, Not set

Inst de Medicina Integral Professor Fernando Figueira- Site Number : 0760006, Recife, Pernambuco

Hospital Ernesto Dornelles Site Number : 0760004, Porto Alegre, Rio Grande Do Sul

Hospital Ernesto Dornelles- Site Number : 0760004, Porto Alegre, Rio Grande Do Sul

Clinica de Alergia Martti Antila- Site Number : 0760002, Sorocaba, São Paulo

Hospital das Clinicas FMUSP- Site Number : 0760001, São Paulo, Not set

Investigational Site Number : 1240002, Edmonton, Alberta

Investigational Site Number : 1240001, Vancouver, British Columbia

Investigational Site Number : 1240008, Burlington, Ontario

Investigational Site Number : 1240007, Hamilton, Ontario

Investigational Site Number : 1240006, Montreal, Quebec

Investigational Site Number : 1240005, Sherbrooke, Quebec

Investigational Site Number : 2030001, Prague, Not set

Investigational Site Number : 2500005, Créteil, Not set

Investigational Site Number : 2500001, Lille, Not set

Investigational Site Number : 2500004, Nice, Not set

Investigational Site Number : 2500002, Paris, Not set

Investigational Site Number : 2500003, Paris, Not set

Investigational Site Number : 2760002, Düsseldorf, Not set

Investigational Site Number : 2760004, Frankfurt, Not set

Investigational Site Number : 2760001, Leipzig, Not set

Investigational Site Number : 3000001, Athens, Not set

Investigational Site Number : 3480005, Budapest, Not set

Investigational Site Number : 3480004, Debrecen, Not set

Investigational Site Number : 3480001, Szigetvár, Not set

Investigational Site Number : 3480002, Székesfehérvár, Not set

Buzzi Children's Hospital - Investigational Site Number : 3800003, Milan, Lombardia

Investigational Site Number : 3800005, Padua, Padova

Ospedale Pediatrico Bambino Gesù - Investigational Site Number : 3800002, Rome, Roma

AOU Luigi Vanvitelli - Investigational Site Number : 3800004, Naples, Not set

Fondazione IRCCS Policlinico San Matteo - Investigational Site Number : 3800001, Pavia, Not set

Investigational Site Number : 3920002, Fukuoka, Not set

Investigational Site Number : 3920001, Fukuoka, Not set

Investigational Site Number : 3920006, Isehara, Not set

Investigational Site Number : 3920004, TSU, Not set

Investigational Site Number : 3920003, Ureshino, Not set

Investigational Site Number : 4840001, San Juan Del Río, Querétaro

Investigational Site Number : 4840004, Durango, Not set

Investigational Site Number : 4840002, Veracruz, Not set

Investigational Site Number : 5280001, Rotterdam, Not set

Investigational Site Number : 6160001, Lodz, Lódzkie

Investigational Site Number : 6160004, Tarnow, Not set

Investigational Site Number : 6160003, Warsaw, Not set

Investigational Site Number : 7240001, Barcelona, Barcelona [Barcelona]

Investigational Site Number : 7240002, Sabadell, Castilla Y León

Investigational Site Number : 7240007, Esplugues de Llobregat, Catalunya [Cataluña]

Investigational Site Number : 7240006, Jerez de La Frontera, Cádiz

Investigational Site Number : 7240003, Santiago de Compostela, Galicia [Galicia]

Investigational Site Number : 7240005, Madrid, Madrid, Comunidad De

Investigational Site Number : 7240004, Valencia, Not set

Investigational Site Number : 8260002, Leicester, Leicestershire

Investigational Site Number : 8260003, Birmingham, Not set

Investigational Site Number : 8260004, Bradford, Not set

Investigational Site Number : 8260001, London, Not set

Conditions: Wheezing, Asthma

Learn More ›

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

NCT03955445

Recruiting

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Gender:

ALL

Ages:

Between 12 years and 100 years

Trial Updated:

08/06/2025

Locations: Childrens Hospital Colorado, Aurora, Colorado +43 locations

Childrens Hospital Colorado, Aurora, Colorado

Georgia Nephrology Research Inst, Lawrenceville, Georgia

University of Iowa Health Care, Iowa City, Iowa

Col Uni Med Center New York Presby, New York, New York

Novartis Investigative Site, Buenos Aires, Not set

Novartis Investigative Site, Belo Horizonte, MG

Novartis Investigative Site, Porto Alegre, RS

Novartis Investigative Site, Botucatu, Sao Paulo

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Beijing, Not set

Novartis Investigative Site, Shanghai, Not set

Novartis Investigative Site, Praha 2, Not set

Novartis Investigative Site, Montpellier 5, Not set

Novartis Investigative Site, Paris 15, Not set

Novartis Investigative Site, Paris, Not set

Novartis Investigative Site, Toulouse, Not set

Novartis Investigative Site, Erlangen, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Mainz, Not set

Novartis Investigative Site, Heraklion Crete, Not set

Novartis Investigative Site, Petach Tikva, Not set

Novartis Investigative Site, Petach-Tikva, Not set

Novartis Investigative Site, Ranica, BG

Novartis Investigative Site, Roma, RM

Novartis Investigative Site, Nagoya, Aichi

Novartis Investigative Site, Asahikawa, Hokkaido

Novartis Investigative Site, Sapporo, Hokkaido

Novartis Investigative Site, Takatsuki, Osaka

Novartis Investigative Site, Ohtsu, Shiga

Novartis Investigative Site, Niigata, Not set

Novartis Investigative Site, Leiden, Zuid Holland

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Pamplona, Navarra

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Bern, Not set

Novartis Investigative Site, Ankara, Not set

Novartis Investigative Site, Kocaeli, Not set

Novartis Investigative Site, Talas Kayseri, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Newcastle upon Tyne, Not set

Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis

Learn More ›

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234

Recruiting

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

Gender:

ALL

Ages:

Between 25 years and 65 years

Trial Updated:

08/06/2025

Locations: GSK Investigational Site, Bruxelles, Not set +13 locations

Conditions: Kidney Disease

Learn More ›

Pompe Disease Registry Protocol

NCT00231400

Recruiting

The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More

Gender:

ALL

Ages:

All

Trial Updated:

08/06/2025

Locations: University Alabama at Birmingham- Site Number : 840106, Birmingham, Alabama +270 locations

University Alabama at Birmingham- Site Number : 840106, Birmingham, Alabama

Barrow Neurological Institute- Site Number : 840087, Phoenix, Arizona

Phoenix Children's Hospital- Site Number : 840003, Phoenix, Arizona

University of Arizona- Site Number : 840015, Tucson, Arizona

Arkansas Childrens Hospital- Site Number : 840109, Little Rock, Arkansas

University of Arkansas for Medical Sciences- Site Number : 840113, Little Rock, Arkansas

University of California at Irvine- Site Number : 840036, Irvine, California

Loma Linda University- Genetics- Site Number : 840070, Loma Linda, California

Southern California Permanente Medical Group- Site Number : 840108, Los Angeles, California

USC Health Sciences Center Dept of Genetics- Site Number : 840082, Los Angeles, California

Children's Hospital Oakland- Site Number : 840029, Oakland, California

Children's Hospital of Orange County- Site Number : 840074, Orange, California

UC Davis MIND Institute- Site Number : 840010, Sacramento, California

University of California at San Diego- Site Number : 840007, San Diego, California

University of California at San Francisco- Site Number : 840051, San Francisco, California

Stanford University Pediatrics- Site Number : 840021, Stanford, California

Children's Hospital Colorado - Aurora- Site Number : 840069, Aurora, Colorado

Yale - Site Number : 840047, New Haven, Connecticut

Children's National Medical Center- Site Number : 840067, Washington, District of Columbia

University of Florida College of Medicine- Site Number : 840012, Gainesville, Florida

University of Florida Pediatrics Genetics- Site Number : 840121, Jacksonville, Florida

University Of Miami SOM- Site Number : 840006, Miami, Florida

University of Florida-Genetics- Site Number : 840096, Tampa, Florida

Emory University School of Medicine- Human Genetics- Site Number : 840060, Decatur, Georgia

University of Colorado at Denver Genetics- Site Number : 840068, Aurora, Illinois

Ann and Robert Lurie Children's Hospital- Site Number : 840011, Chicago, Illinois

Ann and Robert Lurie Children's Hospital- Site Number : 840013, Chicago, Illinois

Rush University Medical Center Genetics- Site Number : 840079, Chicago, Illinois

Indianapolis University School of Medicine- Site Number : 840027, Indianapolis, Indiana

University of Iowa- Site Number : 840032, Iowa City, Iowa

University of Kansas Medical Center- Site Number : 840020, Kansas City, Kansas

University of Louisville- Genetics- Site Number : 840030, Louisville, Kentucky

Maine Medical Center Pediatrics- Site Number : 840064, Portland, Maine

John Hopkins- Site Number : 840044, Baltimore, Maryland

Massachusetts General Hospital-Genetics- Site Number : 840062, Boston, Massachusetts

Boston Children's Hospital- Site Number : 840092, Boston, Massachusetts

Baystate Health- Site Number : 840002, Springfield, Massachusetts

University of Michigan Pediatrics- Site Number : 840107, Ann Arbor, Michigan

Children's Hospital of Michigan- Site Number : 840066, Detroit, Michigan

Spectrum for Health- Site Number : 840019, Grand Rapids, Michigan

Infusion Associates- Site Number : 840050, Grand Rapids, Michigan

Children's Health Care- Site Number : 840114, Minneapolis, Minnesota

Children's Hospital and Clinics of Minnesota- Site Number : 840046, Minneapolis, Minnesota

University of Minnesota Medical Center Pediatrics- Site Number : 840035, Minneapolis, Minnesota

University of Minnesota Medical Center Pediatrics- Site Number : 840076, Minneapolis, Minnesota

University of Missouri Health System Department of Genetics- Site Number : 840031, Columbia, Missouri

Children's Mercy Hospital- Pediatrics- Site Number : 840063, Kansas City, Missouri

Washington University of St. Louis- Site Number : 840100, Saint Louis, Missouri

University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska

Children's Specialty Center of Nevada- Site Number : 840008, Las Vegas, Nevada

Cooper Health Center- Site Number : 840098, Camden, New Jersey

Hackensack University Medical Center- Site Number : 840101, Hackensack, New Jersey

Atlantic Health System- Site Number : 840099, Morristown, New Jersey

St. Peter's University Hospital- Site Number : 840016, New Brunswick, New Jersey

St. Joseph's Children's Hospital- Site Number : 840057, Paterson, New Jersey

Northwell Health- Site Number : 840102, Manhasset, New York

New York University School Of Medicine- Site Number : 840040, New York, New York

Metropolitan Hospital Center- Site Number : 840110, New York, New York

Mt. Sinai School of Medicine- Site Number : 840005, New York, New York

University of Rochester Medical Center SOM- Site Number : 840105, Rochester, New York

State University of New York- Site Number : 840052, Syracuse, New York

New York Medical College- Site Number : 840039, Valhalla, New York

Carolinas Medical Center Hospital- Site Number : 840065, Charlotte, North Carolina

Duke University Medical Center Genetics Dept- Site Number : 840037, Durham, North Carolina

University of Cincinnati Cancer Institute- Site Number : 840124, Cincinnati, Ohio

Cincinnati Children's Hospital-Genetics- Site Number : 840041, Cincinnati, Ohio

University Hospitals Cleveland Medical Center- Site Number : 840119, Cleveland, Ohio

Cleveland Clinic Foundation Pediatrics- Site Number : 840048, Cleveland, Ohio

Nationwide Children's Hospital- Site Number : 840091, Columbus, Ohio

LSD Data Registry Site LLC- Site Number : 840094, Dublin, Ohio

Oregon Health & Sciences University- Site Number : 840080, Portland, Oregon

Oregon Health and Science University- Site Number : 840095, Portland, Oregon

Oregon Health and Scinece University- Site Number : 840038, Portland, Oregon

Penn Hershey Medical Center- Site Number : 840061, Hershey, Pennsylvania

Penn State Health Milton South Hershey Medical Center- Site Number : 840126, Hershey, Pennsylvania

Children's Hospital of Philadelphia HUP Medical Genetics- Site Number : 840089, Philadelphia, Pennsylvania

Children's Hospital of Philadelphia- Site Number : 840034, Philadelphia, Pennsylvania

UPMC- Site Number : 840014, Pittsburgh, Pennsylvania

University of Pittsburgh- Site Number : 840023, Pittsburgh, Pennsylvania

Rhode Island Hospital Genetics- Site Number : 840053, Providence, Rhode Island

Greenwood Genetcs- Site Number : 840055, Greenville, South Carolina

Vanderbilt University Hospital-Pediatrics- Site Number : 840049, Nashville, Tennessee

Baylor Research Center- Site Number : 840058, Dallas, Texas

Cook Children's Health Care System- Site Number : 840024, Fort Worth, Texas

University of Utah Department of Medical Genetics- Site Number : 840043, Salt Lake City, Utah

University of Virginia School of Medicine-Pediatrics- Site Number : 840078, Charlottesville, Virginia

O&O Alpan, LLC- Site Number : 840025, Fairfax, Virginia

Children's Hospital of the Kings Daughters- Site Number : 840072, Norfolk, Virginia

Seattle Children's Hospital- Site Number : 840028, Seattle, Washington

University Of Washington Medical Center- Site Number : 840059, Seattle, Washington

Multicare Health System ¿ Mary Bridge Childrens Hospital- Site Number : 840115, Tacoma, Washington

Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin

Investigational Site Number : 152218, Caba, Buenos Aires

Investigational Site Number : 153194, Caba, Buenos Aires

Investigational Site Number : 153032, Ciudad Autónoma de Buenos Aires, Buenos Aires

Investigational Site Number : 036013, Westmead, New South Wales

Investigational Site Number : 151069, Westmead, New South Wales

Investigational Site Number : 154087, Brisbane, Queensland

Investigational Site Number : 152096, Brisbane, Queensland

Investigational Site Number : 151015, Murdoch, Western Australia

Investigational Site Number : 150722, Antwerp, Not set

Investigational Site Number : 154298, Bruges, Not set

Investigational Site Number : 056010, Brussels, Not set

Investigational Site Number : 150684, Bruxelles, Not set

Investigational Site Number : 152072, Edegem, Not set

Investigational Site Number : 152295, Gent, Not set

Investigational Site Number : 153179, Gosselies, Not set

Investigational Site Number : 151668, Leuven, Not set

Investigational Site Number : 152126, Leuven, Not set

Hospital Universitario Walter Cantidio- Site Number : 076011, Fortaleza, Ceará

Hospital Geral e Maternidade de Cuiabá- Site Number : 076003, Cuiabá, Mato Grosso

Hospital de Clinicas de Porto Alegre- Site Number : 076008, Porto Alegre, Rio Grande Do Sul

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 076009, Ribeirão Preto, São Paulo

Instituto Fernandes Figueira - FIOCRUZ- Site Number : 076001, Rio de Janeiro, Not set

Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 076002, São Paulo, Not set

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 076004, São Paulo, Not set

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 076007, São Paulo, Not set

Investigational Site Number : 100001, Sofia, Not set

Investigational Site Number : 124014, Calgary, Alberta

Investigational Site Number : 124002, Edmonton, Alberta

Investigational Site Number : 124010, Vancouver, British Columbia

Investigational Site Number : 124011, Vancouver, British Columbia

Investigational Site Number : 124019, Winnipeg, Manitoba

Investigational Site Number : 124022, Moncton, New Brunswick

Investigational Site Number : 124007, Hamilton, Ontario

Investigational Site Number : 124021, London, Ontario

Investigational Site Number : 124006, Toronto, Ontario

Investigational Site Number : 124004, Montreal, Quebec

Investigational Site Number : 124018, Montreal, Quebec

Investigational Site Number : 124001, Sherbrooke, Quebec

Investigational Site Number : 152002, Punta Arenas, Not set

Investigational Site Number : 152001, Santiago, Not set

Investigational Site Number : 152380, Beijing, Not set

Investigational Site Number : 153202, Beijing, Not set

Investigational Site Number : 153203, Beijing, Not set

Investigational Site Number : 152379, Guangzhou, Not set

Investigational Site Number : 152381, Jinan, Not set

Investigational Site Number : 157250, Jinan, Not set

Investigational Site Number : 152356, Shanghai, Not set

Investigational Site Number : 152382, Shanghai, Not set

Investigational Site Number : 170001, Bogota, Not set

Investigational Site Number : 1910001, Zagreb, Not set

Investigational Site Number : 1910002, Zagreb, Not set

Investigational Site Number : 150809, Praha 2, Not set

Investigational Site Number : 151229, København Ø, Not set

Investigational Site Number : 250010, Bordeaux, Not set

Investigational Site Number : 250012, Brest, Not set

Investigational Site Number : 250003, BRON Cedex, Not set

Investigational Site Number : 250007, BRON Cedex, Not set

Investigational Site Number : 250009, Caen, Not set

Investigational Site Number : 250015, La Tronche, Not set

Investigational Site Number : 250008, Lille, Not set

Investigational Site Number : 250002, Marseille Cedex 05, Not set

Investigational Site Number : 250017, Nancy, Not set

Investigational Site Number : 250019, Nantes, Not set

Investigational Site Number : 250005, Nice, Not set

Investigational Site Number : 250011, Nîmes, Not set

Investigational Site Number : 250004, Paris, Not set

Investigational Site Number : 250001, Paris, Not set

Investigational Site Number : 250018, St Priest en Jarez, Not set

Investigational Site Number : 250016, Strasbourg, Not set

Investigational Site Number : 250014, Toulouse, Not set

Investigational Site Number : 250006, Tours, Not set

Investigational Site Number : 25013, Vannes Cedex, Not set

Investigational Site Number : 152041, Berlin, Not set

Investigational Site Number : 151686, Berlin, Not set

Investigational Site Number : 152293, Berlin, Not set

Investigational Site Number : 152234, Bochum, Not set

Investigational Site Number : 152200, Bonn, Not set

Investigational Site Number : 152108, Freiburg, Not set

Investigational Site Number : 154150, Gießen, Not set

Investigational Site Number : 152045, Halle (Saale), Not set

Investigational Site Number : 154215, Hamburg, Not set

Investigational Site Number : 150031, Mainz, Not set

Investigational Site Number : 152075, München, Not set

Investigational Site Number : 152299, Münster, Not set

Investigational Site Number : 300001, Thessaloniki, Not set

Investigational Site Number : 344001, Kowloon, Not set

Investigational Site Number : 3480009, Debrecen, Not set

Investigational Site Number : 3480007, Nyíregyháza, Not set

Investigational Site Number : 3480011, Pécs, Not set

Investigational Site Number : 356003, Ahmedabad, Not set

Investigational Site Number : 356001, Kolkata, Not set

Investigational Site Number : 3560004, Secunderabad, Not set

Investigational Site Number : 356002, Vellore, Not set

Investigational Site Number : 360001, Jakarta, Not set

Investigational Site Number : 3760002, Beer Sheva, Not set

Investigational Site Number : 3760001, Haifa, Not set

Investigational Site Number : 3760003, Tel Aviv, Not set

Investigational Site Number : 380007, Milan, Milano

Investigational Site Number : 380011, Padua, Padova

Investigational Site Number : 380008, Brescia, Not set

Investigational Site Number : 380006, Cagliari, Not set

Investigational Site Number : 380014, Ferrara, Not set

Investigational Site Number : 380005, Firenze, Not set

Investigational Site Number : 380004, Genova, Not set

Investigational Site Number : 380013, Messina, Not set

Investigational Site Number : 380016, Milano, Not set

Investigational Site Number : 380009, Monza, Not set

Investigational Site Number : 380010, Napoli, Not set

Investigational Site Number : 380019, Napoli, Not set

Investigational Site Number : 380002, Padova, Not set

Investigational Site Number : 380003, Pavia, Not set

Investigational Site Number : 157218, Pisa, Not set

Investigational Site Number : 380015, Roma, Not set

Investigational Site Number : 380012, Roma, Not set

Investigational Site Number : 380017, Torino, Not set

Investigational Site Number : 380001, Udine, Not set

Investigational Site Number : 392106, Sakyo-ku, Kyoto

Investigational Site Number : 392105, Ginowan, Okinawa

Investigational Site Number : 4000001, Amman, Not set

Investigational Site Number : 153178, Yangsan-si, Gyeongsangnam-do

Investigational Site Number : 153180, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 153196, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 153176, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 153191, Daejeon, Not set

Investigational Site Number : 153192, Seoul, Not set

Investigational Site Number : 151149, Seoul, Not set

Investigational Site Number : 153212, Seoul, Not set

Investigational Site Number : 153222, Seoul, Not set

Investigational Site Number : 154225, Kuwait, Not set

Investigational Site Number : 4220004, Beirut, Not set

Investigational Site Number : 458001, Jalan Pahang, Not set

Investigational Site Number : 458002, Kuala Lumpur, Not set

Investigational Site Number : 152029, Rotterdam, Not set

Investigational Site Number : 154264, Karachi, Not set

Investigational Site Number : 154266, Lahore, Not set

Investigational Site Number : 608001, Manila, Not set

Investigational Site Number : 150575, Warszawa, Not set

Investigational Site Number : 620008, Coimbra, Not set

Investigational Site Number : 620006, Lisboa, Not set

Investigational Site Number : 154099, Bucuresti, Not set

Investigational Site Number : 643002, Moscow, Not set

Investigational Site Number : 682004, Makkah, Not set

Investigational Site Number : 682001, Qatif, Not set

Investigational Site Number : 6880001, Belgrade, Not set

Investigational Site Number : 702001, Singapore, Not set

Investigational Site Number : 703001, Bratislava, Not set

Investigational Site Number : 154093, Chiayi, Not set

Investigational Site Number : 152152, Hualian, Not set

Investigational Site Number : 152246, Kaohsiung City, Not set

Investigational Site Number : 152244, Kaohsiung, Not set

Investigational Site Number : 151534, New Taipei City, Not set

Investigational Site Number : 151500, Putz City, Chia-yi, Not set

Investigational Site Number : 151181, Taichung, Not set

Investigational Site Number : 151179, Taichung, Not set

Investigational Site Number : 153248, Tainan City, Not set

Investigational Site Number : 152153, Tainan City, Not set

Investigational Site Number : 151182, Taipei City, Not set

Investigational Site Number : 152226, Taipei City, Not set

Investigational Site Number : 152321, Taipei, Not set

Investigational Site Number : 153158, Taoyuan City, Not set

Investigational Site Number : 764002, Bangkok, Not set

Investigational Site Number : 764003, Bangkok, Not set

Investigational Site Number : 764004, Bangkok, Not set

Investigational Site Number : 764001, Bangkok, Not set

Investigational Site Number : 764005, Khon Kaen, Not set

Investigational Site Number : 7840001, Dubai, Not set

Investigational Site Number : 151340, Cambridge, Cambridgeshire

Investigational Site Number : 152334, Cardiff, Cardiff [Caerdydd Gb-crd]

Investigational Site Number : 152287, Birmingham, England

Investigational Site Number : 151646, London, London, City Of

Investigational Site Number : 150303, London, London, City Of

Investigational Site Number : 150964, Salford, Manchester

Investigational Site Number : 154240, Birmingham, Not set

Investigational Site Number : 152156, Glasgow, Not set

Investigational Site Number : 151123, London, Not set

Investigational Site Number : 150455, Manchester, Not set

Investigational Site Number : 152087, Newcastle, Not set

Investigational Site Number : 154212, Hanoi, Not set

Investigational Site Number : 704002, Ho Chi Minh City, Not set

Conditions: Glycogen Storage Disease Type II, Pompe Disease

Learn More ›

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892

Recruiting

The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

08/06/2025

Locations: GSK Investigational Site, Birmingham, Alabama +251 locations

GSK Investigational Site, Birmingham, Alabama

GSK Investigational Site, Huntsville, Alabama

GSK Investigational Site, Phoenix, Arizona

GSK Investigational Site, Tucson, Arizona

GSK Investigational Site, Cerritos, California

GSK Investigational Site, Coral Gables, Florida

GSK Investigational Site, Fort Myers, Florida

GSK Investigational Site, Jacksonville, Florida

GSK Investigational Site, Lake City, Florida

GSK Investigational Site, Melbourne, Florida

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Orlando, Florida

GSK Investigational Site, Pinellas Park, Florida

GSK Investigational Site, The Villages, Florida

GSK Investigational Site, West Palm Beach, Florida

GSK Investigational Site, Atlanta, Georgia

GSK Investigational Site, Savannah, Georgia

GSK Investigational Site, Chicago, Illinois

GSK Investigational Site, Evansville, Indiana

GSK Investigational Site, Mishawaka, Indiana

GSK Investigational Site, El Dorado, Kansas

GSK Investigational Site, Newton, Kansas

GSK Investigational Site, Wichita, Kansas

GSK Investigational Site, Lexington, Kentucky

GSK Investigational Site, Rockville, Maryland

GSK Investigational Site, Richfield, Minnesota

GSK Investigational Site, Kansas City, Missouri

GSK Investigational Site, Saint Louis, Missouri

GSK Investigational Site, Omaha, Nebraska

GSK Investigational Site, Las Vegas, Nevada

GSK Investigational Site, New York, New York

GSK Investigational Site, Rochester, New York

GSK Investigational Site, Hickory, North Carolina

GSK Investigational Site, Mooresville, North Carolina

GSK Investigational Site, Rocky Mount, North Carolina

GSK Investigational Site, Salisbury, North Carolina

GSK Investigational Site, Winston-Salem, North Carolina

GSK Investigational Site, Centerville, Ohio

GSK Investigational Site, Cincinnati, Ohio

GSK Investigational Site, Columbus, Ohio

GSK Investigational Site, Erie, Pennsylvania

GSK Investigational Site, Pittsburgh, Pennsylvania

GSK Investigational Site, Anderson, South Carolina

GSK Investigational Site, Mount Pleasant, South Carolina

GSK Investigational Site, Knoxville, Tennessee

GSK Investigational Site, Memphis, Tennessee

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, Fort Worth, Texas

GSK Investigational Site, Houston, Texas

GSK Investigational Site, Keller, Texas

GSK Investigational Site, San Antonio, Texas

GSK Investigational Site, Salt Lake City, Utah

GSK Investigational Site, Norfolk, Virginia

GSK Investigational Site, Botany, New South Wales

GSK Investigational Site, Coffs Harbour, New South Wales

GSK Investigational Site, Darlinghurst, New South Wales

GSK Investigational Site, Taringa, Queensland

GSK Investigational Site, Tarragindi, Queensland

GSK Investigational Site, Camberwell, Victoria

GSK Investigational Site, Geelong, Victoria

GSK Investigational Site, Spearwood, Western Australia

GSK Investigational Site, Diepenbeek, Not set

GSK Investigational Site, Edegem, Not set

GSK Investigational Site, Erpent, Not set

GSK Investigational Site, Genk, Not set

GSK Investigational Site, Gent, Not set

GSK Investigational Site, Ieper, Not set

GSK Investigational Site, Kluisbergen, Not set

GSK Investigational Site, Linkebeek, Not set

GSK Investigational Site, Mechelen, Not set

GSK Investigational Site, Tremelo, Not set

GSK Investigational Site, Edmonton, Alberta

GSK Investigational Site, New Westminster, British Columbia

GSK Investigational Site, Surrey, British Columbia

GSK Investigational Site, Vancouver, British Columbia

GSK Investigational Site, Victoria, British Columbia

GSK Investigational Site, Halifax, Nova Scotia

GSK Investigational Site, Truro, Nova Scotia

GSK Investigational Site, London-Ontario, Ontario

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Sarnia, Ontario

GSK Investigational Site, Sudbury, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Chicoutimi, Quebec

GSK Investigational Site, Mirabel, Quebec

GSK Investigational Site, Pointe-Claire, Quebec

GSK Investigational Site, Sainte-Foy, Quebec

GSK Investigational Site, Sherbrooke, Quebec

GSK Investigational Site, St-Charles-Borromee, Quebec

GSK Investigational Site, Quebec, Not set

GSK Investigational Site, Paide, Not set

GSK Investigational Site, Tallinn, Not set

GSK Investigational Site, Tartu, Not set

GSK Investigational Site, Espoo, Not set

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Jarvenpaa, Not set

GSK Investigational Site, Kokkola, Not set

GSK Investigational Site, Oulu, Not set

GSK Investigational Site, Seinajoki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Turku, Not set

GSK Investigational Site, Weinheim, Baden-Wuerttemberg

GSK Investigational Site, Muenchen, Bayern

GSK Investigational Site, Freiberg, Sachsen

GSK Investigational Site, Berlin, Not set

GSK Investigational Site, Dachau, Not set

GSK Investigational Site, Dippoldiswalde, Not set

GSK Investigational Site, Dresden, Not set

GSK Investigational Site, Essen, Not set

GSK Investigational Site, Frankfurt, Not set

GSK Investigational Site, Freital, Not set

GSK Investigational Site, Goch, Not set

GSK Investigational Site, Hamburg, Not set

GSK Investigational Site, Hannover, Not set

GSK Investigational Site, Hochheim am Main, Not set

GSK Investigational Site, Koeln, Not set

GSK Investigational Site, Leipzig, Not set

GSK Investigational Site, Mainz, Not set

GSK Investigational Site, Schenefeld, Not set

GSK Investigational Site, Wallerfing, Not set

GSK Investigational Site, Wangen, Not set

GSK Investigational Site, Witten, Not set

GSK Investigational Site, Wuerzburg, Not set

GSK Investigational Site, Alessandria, Not set

GSK Investigational Site, Bari, Not set

GSK Investigational Site, Belluno, Not set

GSK Investigational Site, Ferrara, Not set

GSK Investigational Site, Napoli, Not set

GSK Investigational Site, Negrar Verona, Not set

GSK Investigational Site, Palermo, Not set

GSK Investigational Site, Pessione - Chieri TO, Not set

GSK Investigational Site, Pisa, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Siena, Not set

GSK Investigational Site, Hiroshima, Not set

GSK Investigational Site, Ibaraki, Not set

GSK Investigational Site, Kumamoto, Not set

GSK Investigational Site, Okinawa, Not set

GSK Investigational Site, Saitama, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Yamagata, Not set

GSK Investigational Site, Yamaguchi, Not set

GSK Investigational Site, Ansan, Not set

GSK Investigational Site, Bucheon-si Kyunggi-do 14584, Not set

GSK Investigational Site, Daegu, Not set

GSK Investigational Site, Incheon, Not set

GSK Investigational Site, Jeonju, Not set

GSK Investigational Site, Kangwon-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Suwon Gyeonggi-do, Not set

GSK Investigational Site, Chihuahua, Not set

GSK Investigational Site, Leon, Not set

GSK Investigational Site, Merida, Not set

GSK Investigational Site, Mexico City, Not set

GSK Investigational Site, Monterrey, Not set

GSK Investigational Site, Oaxaca, Not set

GSK Investigational Site, Queretaro, Not set

GSK Investigational Site, RM Pharmamexico CITY, Not set

GSK Investigational Site, San Luis PotosI, Not set

GSK Investigational Site, Grafton Auckland, Not set

GSK Investigational Site, Hawke's Bay, Not set

GSK Investigational Site, Kapiti, Not set

GSK Investigational Site, Palmerston North, Not set

GSK Investigational Site, Tauranga, Not set

GSK Investigational Site, Wellington, Not set

GSK Investigational Site, Czestochowa, Not set

GSK Investigational Site, Elblag, Not set

GSK Investigational Site, Gdansk, Not set

GSK Investigational Site, Gdynia, Not set

GSK Investigational Site, Katowice, Not set

GSK Investigational Site, Krakow, Not set

GSK Investigational Site, Lodz, Not set

GSK Investigational Site, Poznan, Not set

GSK Investigational Site, Warsaw, Not set

GSK Investigational Site, Warszawa, Not set

GSK Investigational Site, Wroclaw, Not set

GSK Investigational Site, Gatchina, Leningrad Region

GSK Investigational Site, Barnaul, Not set

GSK Investigational Site, Ekaterinburg, Not set

GSK Investigational Site, Kemerovo, Not set

GSK Investigational Site, Moscow, Not set

GSK Investigational Site, Saint-Petersburg, Not set

GSK Investigational Site, StPetersburg, Not set

GSK Investigational Site, Bloemfontein, Not set

GSK Investigational Site, Cape Town, Not set

GSK Investigational Site, Johannesburg, Not set

GSK Investigational Site, Middelburg, Not set

GSK Investigational Site, Moloto South, Not set

GSK Investigational Site, Reiger Park, Not set

GSK Investigational Site, Tembisa, Not set

GSK Investigational Site, AlcorcOn, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Santiago de Compostela, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Bebington, Not set

GSK Investigational Site, Belfast, Not set

GSK Investigational Site, Birmingham, Not set

GSK Investigational Site, Bradford On Avon Wiltsh, Not set

GSK Investigational Site, Cardiff, Not set

GSK Investigational Site, Corby, Not set

GSK Investigational Site, Eynsham, Not set

GSK Investigational Site, Glasgow, Not set

GSK Investigational Site, Hexham, Not set

GSK Investigational Site, Lancashire, Not set

GSK Investigational Site, Leamington Spa, Not set

GSK Investigational Site, Liverpool, Not set

GSK Investigational Site, Manchester, Not set

GSK Investigational Site, Orpington, Not set

GSK Investigational Site, Oxford, Not set

GSK Investigational Site, Peterborough, Not set

GSK Investigational Site, Thetford, Not set

GSK Investigational Site, Witney, Not set

Conditions: Respiratory Syncytial Virus Infections

Learn More ›

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478

Recruiting

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy a... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/06/2025

Locations: Yale Cancer Center, New Haven, Connecticut +244 locations

Yale Cancer Center, New Haven, Connecticut

Orchard Healthcare Research Inc., Skokie, Illinois

University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas

Maryland Oncology Hematology, P.A., Silver Spring, Maryland

Tufts Medical Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor, Michigan

Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota

Montefiore Medical Center, Bronx, New York

Memorial Sloan Kettering Cancer Center - MAIN, New York, New York

Providence Portland Medical Center, Portland, Oregon

Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania

Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina

Tennessee Oncology Nashville Midtown, Nashville, Tennessee

UT Southwestern Medical Center, Dallas, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

Virginia Oncology Associates, Norfolk, Virginia

Blue Ridge Cancer Care, Roanoke, Virginia

Wenatchee Valley Hospital & Clinics, Wenatchee, Washington

CEMIC Ciudad Autonoma, Buenos Aires, Not set

Instituto Medico Especializado Alexander Fleming, Buenos Aires, Not set

Clinica Universitaria Privada Reina Fabiola, Cordoba, Not set

Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Not set

Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Not set

Flinders Medical Centre, Bedford Park, Not set

Monash Medical Centre Clayton, Clayton, Not set

Townsville University Hospital, Douglas, Not set

Peter MacCallum Cancer Centre, North Melbourne, Not set

GenesisCare North Shore (Oncology), St Leonards, Not set

St John of God Subiaco Hospital, Subiaco, Not set

Wollongong Hospital, Wollongong, Not set

LKH - Universitaetsklinikum Graz, Graz, Not set

Medizinische Universität Innsbruck, Innsbruck, Not set

St. Josef Krankenhaus Wien, Vienna, Not set

Landesklinikum Wiener Neustadt, Wiener Neustadt, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Not set

AZ Sint-Lucas, Brugge, Not set

Cliniques Universitaires Saint-Luc, Bruxelles, Not set

UZ Leuven, Leuven, Not set

Centre Hospitalier Universitaire de Liege, Liege, Not set

CHU UCL Namur, Namur, Not set

Centro de Oncologia - Unidade Brasilia - Hospital Sirio Libanes, Brasilia, Not set

ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira Sao Paulo, Brazil, Not set

CEPON - Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Not set

Fundação Doutor Amaral Carvalho, Jaú, Not set

Liga Norte-Rio-Grandense Contra o Câncer, Natal, Not set

Hospital de Clínicas de Porto Alegre, Porto Alegre, Not set

Hospital São Lucas da PUCRS, Porto Alegre, Not set

IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Recife, Not set

Hospital das Clínicas FMRP-USP, Ribeirão Preto, Not set

INCA - Instituto Nacional de Câncer, Rio de Janeiro, Not set

Obras Sociais Irmã Dulce - Hospital Santo Antônio, Salvador, Not set

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Not set

Cité de la Santé de Laval, Laval, Not set

CHUS - Hôtel-Dieu, Sherbrooke, Not set

Mount Sinai Hospital, Toronto, Not set

Sunnybrook Health Sciences Centre, Toronto, Not set

University Health Network - Princess Margaret Cancer Centre, Toronto, Not set

Biocenter, Concepcion, Not set

URUMED Spa, Rancagua, Not set

Centro de Investigacion del Maule, Region Del Maule, Not set

Centro de Estudios Clinicos SAGA, Santiago, Not set

FALP - Fundación Arturo López Pérez, Santiago, Not set

Hospital Clinico Universidad de Chile, Santiago, Not set

Beijing Cancer Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Fujian Cancer Hospital, Fuzhou, Not set

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Not set

The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Anhui Provincial Cancer Hospital, Hefei City, Not set

Shandong Cancer Hospital, Jinan, Not set

Gansu Provincial Cancer Hospital, Lanzhou, Not set

Lanzhou University Second Hospital, Lanzhou, Not set

Linyi Cancer Hospital, Linyi, Not set

Meizhou People's Hospital, Meizhou, Not set

Liaoning Cancer Hospital & Institute, Shenyang, Not set

The Second Affiliated Hospital of Soochow University, Suzhou, Not set

Shanxi Provincial Cancer Hospital, Taiyuan, Not set

Shanxi Provincial People's Hospital, Taiyuan, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

The Affiliated Cancer Hospital of Xinjiang Medical university, Urumqi, Not set

Hubei Cancer Hospital, Wuhan, Not set

Wuxi 4th People's Hospital, Wuxi, Not set

The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Not set

The First Affiliated Hospital of Xiamen University, Xiamen, Not set

Fudan University Shanghai Cancer Center, Xuhui District, Not set

Xuzhou Central Hospital, Xuzhou, Not set

General Hospital of Ningxia Medical University, Yinchuan, Not set

Masarykuv onkologicky ustav, Brno, Not set

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set

Fakultni nemocnice Olomouc, Olomouc, Not set

Fakultni nemocnice v Motole, Praha 5, Not set

Institut Sainte Catherine, Avignon Cedex 9, Not set

CHU de Brest - Hopital de la Cavale Blanche, Brest, Not set

Centre Georges François Leclerc, Dijon cedex, Not set

CHU Grenoble - Hopital Michallon, Grenoble, Not set

Centre Oscar Lambret, Lille cedex, Not set

Hopital Prive Jean Mermoz, Lyon Cedex 08, Not set

CHU Montpellier, Saint Eloi, Montpellier, Not set

Chru De Nantes Hotel-Dieu, Nantes Cedex 01, Not set

Hôpital Saint-Antoine, Paris cedex 12, Not set

Hôpital Européen Georges Pompidou, Paris Cedex 15, Not set

Institut Mutualiste Montsouris, Paris, Not set

CHU Bordeaux - Hôpital Haut-Lévêque, Pessac, Not set

CHU Poitiers - Hôpital la Milétrie, Poitiers Cedex, Not set

Institut de Cancérologie de Strasbourg Europe - ICANS, Strasbourg, Not set

Hôpital Foch, Suresnes Cedex, Not set

Hopital Rangueil, Toulouse Cedex 9, Not set

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Not set

Vivantes Klinikum im Friedrichshain, Berlin, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Not set

Universitaetsklinikum Frankfurt Goethe-Universitaet, Frankfurt am Main, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitaetsklinikum Leipzig AoeR, Leipzig, Not set

Klinikum rechts der Isar der TU Muenchen, Muenchen, Not set

Presidio Ospedaliero Garibaldi Nesima, Catania, Not set

Azienda Ospedaliera Universitaria Careggi, Florenze, Not set

IRCCS Ospedale Policlinico San Martino, Genova, Not set

Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda), Milano, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Ospedale San Raffaele, Milano, Not set

A.O.U. Policlinico di Modena, Modena, Not set

Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Not set

IOV - Istituto Oncologico Veneto IRCCS, Padova, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Azienda Unità Sanitaria Locale- Ravenna, Ravenna, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Not set

Istituto Clinico Humanitas, Rozzano, Not set

IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Not set

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Not set

Azienda Ospedaliera Card. G. Panico, Tricase, Not set

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku, Not set

National Cancer Center Hospital, Chuo-ku, Not set

Gifu University Hospital, Gifu-shi, Not set

Hiroshima City Hiroshima Citizens Hospital, Hiroshima-shi, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

JCHO Kyushu Hospital, Kitakyushu, Not set

Kochi Health Sciences Center, Kochi-shi, Not set

Cancer Institute Hospital of JFCR, Koto-ku, Not set

NHO Shikoku Cancer Center, Matsuyama-shi, Not set

Aichi Cancer Center Hospital, Nagoya-shi, Not set

Miyagi Cancer Center, Natori-shi, Not set

Niigata Cancer Center Hospital, Niigata-shi, Not set

Osaka International Cancer Institute, Osaka-shi, Not set

Kindai University Hospital, Osakasayama-shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

Osaka University Hospital, Suita-shi, Not set

Kanagawa Cancer Center, Yokohama-shi, Not set

Chungbuk National University Hospital, Cheongju-si, Not set

Kyungpook National University Chilgok Hospital, Daegu, Not set

National Cancer Center, Goyang-si, Not set

Chonnam National University Hwasun Hospital, Hwasun-gun, Not set

Gachon University Gil Medical Center, Incheon, Not set

Jeonbuk national university hospital, Jeonju-si, Not set

CHA Bundang Medical Center, CHA University, Seongnam-si, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Korea University Anam Hospital, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Antoni van Leeuwenhoek, Amsterdam, Not set

Medisch Centrum Leeuwarden, Leeuwarden, Not set

Radboudumc, Nijmegen, Not set

Erasmus Medisch Centrum, Rotterdam, Not set

ETZ Elisabeth, Tilburg, Not set

UMC Utrecht, Utrecht, Not set

Haukeland University Hospital, Bergen, Not set

Akershus universitetssykehus HF, Lørenskog, Not set

Oslo Universitetssykehus HF, Ullevål, Oslo, Not set

St. Olavs Hospital Hf, Universitetssykehuset i Trondheim, Trondheim, Not set

Beskidzkie Centrum Onkologii im.Jana Pawla II, Bielsko-Biała, Not set

Szpital Wojewodzki im. Mikolaja Kopernika, Koszalin, Not set

Wielkopolskie Centrum Onkologii, Poznan, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy W Warszawie, Warsaw, Not set

Warszawski Uniwersytet Medyczny, Warsaw, Not set

Hospital de Braga, Braga, Not set

Hospital da Senhora da Oliveira Guimarães, E.P.E., Guimarães, Not set

Fundação Champalimaud, Lisboa, Not set

Hospital da Luz, Lisboa, Not set

Unidade Local de Saúde de Santa Maria, E.P.E. - Hospital de Santa Maria, Lisboa, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Not set

Institutul Clinic Fundeni, Bucuresti, Not set

Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj Napoca, Cluj Napoca, Not set

S.C Medisprof S.R.L, Cluj-Napoca, Not set

Centrul de Oncologie Sfantul Nectarie Craiova, Craiova, Not set

Institutul Regional de Oncologie Iasi, Iasi, Not set

S.C Ovidius Clinical Hospital S.R.L, Ovidiu, Not set

S.C. Sigmedical Services SRL, Suceava, Not set

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital del Mar, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Universitario Reina Sofia, Cordoba, Not set

Hospital General Universitario de Elche, Elche, Not set

ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

MD Anderson Cancer Centre, Madrid, Not set

Hospital General Universitario Morales Meseguer, Murcia, Not set

Hospital Regional Universitario de Malaga, Málaga, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario de Navarra, Pamplona, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei, Not set

National Taiwan University Hospital, Taipei, Not set

Chang Gung Memorial Hospital,Linkou, Taoyuan City, Not set

Siriraj Hospital, Bangkoknoi, Not set

Vajira Hospital, Dusit, Not set

Songklanagarind Hospital, Hatyai, Not set

Chulabhorn Hospital, Laksi, Not set

King Chulalongkorn Memorial Hospital, Pathum Wan, Not set

Medical Park Seyhan Hospital, Adana, Not set

Ankara City Hospital, Ankara, Not set

Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, Not set

Hacettepe University Medical Faculty, Ankara, Not set

Dicle University, Medical faculty, Diyarbakir, Not set

Ataturk University Medical Faculty, Erzurum, Not set

Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Not set

Medipol University Medical Faculty, Istanbul, Not set

İ.E.Ü. Medicalpoint İzmir Hastanesi, Izmir, Not set

Medical Park Samsun Hastanesi, Samsun, Not set

Queen Elizabeth Hospital, Birmingham, Not set

Velindre Cancer Centre, Cardiff, Not set

Ninewells Hospital, Dundee, Not set

Castle Hill Hospital, Hull, Not set

St James's University Hospital, Leeds, Not set

Altnagelvin Area Hospital, Londonderry, Not set

Sarah Cannon Research Institute UK, London, Not set

University College London Hospitals, London, Not set

The Christie Hospital, Manchester, Not set

Royal Marsden Hospital, Sutton, Not set

Hanoi Oncology hospital, Hanoi, Not set

National Cancer Hospital, Hanoi, Not set

Cho Ray Hospital, Ho Chi Minh City, Not set

HCMC Oncology Hospital, Ho Chi Minh city, Not set

HCMC University Medical Center, HoChiMinh, Not set

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer

Learn More ›

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089

Recruiting

This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/06/2025

Locations: Clinical Site, Avondale, Arizona +114 locations

Clinical Site, Avondale, Arizona

Clinical Site, Chandler, Arizona

Clinical Site, Flagstaff, Arizona

Clinical Site, Mesa, Arizona

Clinical Site, Phoenix, Arizona

Clinical Site, Scottsdale, Arizona

Clinical Site, Tucson, Arizona

Clinical Site, Jonesboro, Arkansas

Clinical Site, Pomona, California

Clinical Site, San Diego, California

Clinical Site, Thousand Oaks, California

Clinical Site, Upland, California

Clinical Site, Avon Park, Florida

Clinical Site, Clearwater, Florida

Clinical Site, Hialeah, Florida

Clinical Site, Miami Gardens, Florida

Clinical Site, Tampa, Florida

Clinical Site, Zephyrhills, Florida

Clinical Site, Gainesville, Georgia

Clinical Site, Springfield, Illinois

Clinical Site, Lake Charles, Louisiana

Clinical Site, Grand Blanc, Michigan

Clinical Site, Charlotte, North Carolina

Clinical Site, Leland, North Carolina

Clinical Site, Middleburg Heights, Ohio

Clinical Site, Portland, Oregon

Clinical Site, Duncansville, Pennsylvania

Clinical Site, Jackson, Tennessee

Clinical Site, Memphis, Tennessee

Clinical Site, Murfreesboro, Tennessee

Clinical Site, Allen, Texas

Clinical Site, Austin, Texas

Clinical Site, Baytown, Texas

Clinical Site, Colleyville, Texas

Clinical Site, Houston, Texas

Clinical Site, Lubbock, Texas

Clinical Site, Plano, Texas

Clinical Site, Beckley, West Virginia

Clinical Site, Pleven, Not set

Clinical Site, Plovdiv, Not set

Clinical Site, Ruse, Not set

Clinical Site, Sofia, Not set

Clinical Site, Stara Zagora, Not set

Clinical Site, Calgary, Not set

Clinical Site, Trois-Rivières, Not set

Clinical Site, Waterloo, Not set

Clinical Site, Winnipeg, Not set

Clinical Site, Brno, Not set

Clinical Site, Ostrava, Not set

Clinical Site, Studénka, Not set

Clinical Site, Zlín, Not set

Clinical Site, Caluire-et-Cuire, Not set

Clinical Site, Montpellier, Not set

Clinical Site, Narbonne, Not set

Clinical Site, Nice, Not set

Clinical Site, Rouen, Not set

Clinical Site, Tours, Not set

Clinical Site, Tbilisi, Not set

Clinical Site, Berlin, Not set

Clinical Site, Erlangen, Not set

Clinical Site, Hamburg, Not set

Clinical Site, Herne, Not set

Clinical Site, Muenchen, Not set

Clinical Site, Munich, Not set

Clinical Site, Budapest, Not set

Clinical Site, Debrecen, Not set

Clinical SIte, Gyula, Not set

Clinical Site, Hódmezővásárhely, Not set

Clinical Site, Nyíregyháza, Not set

Clinical Site, Székesfehérvár, Not set

Clinical Site, Veszprém, Not set

Clinical Site, Białystok, Not set

Clinical Site, Bydgoszcz, Not set

Clinical Site, Częstochowa, Not set

Clinical Site, Elbląg, Not set

Clinical Site, Kraków, Not set

Clinical Site, Nadarzyn, Not set

Clinical Site, Poznań, Not set

Clinical Site, Sochaczew, Not set

Clinical Site, Warsaw, Not set

Clinical Site, Warszawa, Not set

Clinical Site, Wołomin, Not set

Clinical Site, Wrocław, Not set

Clinical Site, Świdnica, Not set

Clinical Site, A Coruña, Not set

Clinical Site, Castellón De La Plana, Not set

Clinical Site, Madrid, Not set

Clinical SIte, Sabadell, Not set

Clinical Site, Santiago De Compostela, Not set

Clinical Site, Sevilla, Not set

Clinical Site, Barnet, Not set

Clinical Site, Leeds, Not set

Conditions: Arthritis, Psoriatic

Learn More ›